Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The interest coverage ratio is N/A as of Tuesday, October 6, 2026.
INTEREST COVERAGE RATIO
N/A
Atrium Therapeutics, Inc.
Market Cap
$137.40M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$137.60M
Interest Coverage Ratio
N/A
TTM Avg
346.24x
3Y Avg
936.28x
5Y Avg
577.46x
Market Cap
$136.55M
Interest Coverage Ratio
N/A
TTM Avg
2.09x
3Y Avg
2.35x
5Y Avg
2.35x
Market Cap
$139.01M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$140.31M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$141.12M
Interest Coverage Ratio
-2.75x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | $137.40M | N/A | N/A | N/A | N/A |
| KORU Medical Systems, Inc. (KRMD)vs › | $137.60M | N/A | 346.24x | 936.28x | 577.46x |
| Organigram Global Inc. (OGI)vs › | $136.55M | N/A | 2.09x | 2.35x | 2.35x |
| Alpha Cognition Inc (ACOG)vs › | $139.01M | N/A | N/A | N/A | N/A |
| Immuneering Corporation (IMRX)vs › | $140.31M | N/A | N/A | N/A | N/A |
| Sutro Biopharma, Inc. (STRO)vs › | $141.12M | -2.75x | N/A | N/A | N/A |
| LifeMD, Inc. (LFMD)vs › | $132.76M | -5.64x | N/A | N/A | N/A |
| Nyxoah S.A. (NYXH)vs › | $142.60M | -49.05x | N/A | N/A | N/A |
| Freenome, Inc. (FRNM)vs › | $132.31M | N/A | N/A | N/A | N/A |
| AirSculpt Technologies, Inc. (AIRS)vs › | $131.57M | -0.80x | 1.46x | 2.93x | 2.25x |
Interest Coverage
N/A
Debt/Equity
0.01
Current Ratio
8.73
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
